Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 9/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12293252 | 0.83 | GPR84 (0.53) | GPR84HTR2ATDO2HTR1AMEN1 | |
| SCHEMBL20110126 | 0.82 | HTR2A (0.44) | HTR2AMEN1KMT2A | |
| SCHEMBL22122315 | 0.81 | CYP2A6 (0.45) | GPR84 | |
| SCHEMBL5646170 | 0.80 | GPR84 (0.50) | GPR84HTR2ATDO2HTR1AMEN1 | |
| SCHEMBL1241309 | 0.76 | HTR2A (0.53) | GPR84HTR2ATDO2HTR1AKMT2A | |
| SCHEMBL997167 | 0.76 | IMPDH2 (0.52) | GPR84MEN1KMT2A | |
| SCHEMBL30275204 | 0.75 | TDO2 (0.51) | GPR84HTR2ATDO2MEN1KMT2A | |
| SCHEMBL27630028 | 0.75 | GPR84 (0.45) | GPR84HTR2ATDO2HTR1AMEN1 | |
| Hydrochloric Acid SCHEMBL1243732 | 0.75 | HTR2A (0.51) | GPR84HTR2ATDO2HTR1AKMT2A | |
| SCHEMBL18103497 | 0.73 | HTR1B (0.44) | HTR2AHTR1AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2021-07-15 | — | — | US | disclosed |
| US-10421759-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. | 2018-05-03 | — | — | US | disclosed |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. | 2018-05-03 | — | — | US | disclosed |
| WO-2016151403-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2016-09-29 | — | — | WO | disclosed |
| EP-2334681-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | Wyeth LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | WYETH (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2010036362-A1 | 1,2,3,6-TETRAHYDROAZEPINO[4,5-B]INDOLE-5-CARBOXYLATE NUCLEAR RECEPTOR INHIBITORS | WYETH (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421759-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | GPR84 3671/4885HTR2A 4579/4885TDO2 4294/4885 |
| US-20110039824-A1 | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors | NR1H4, NR1H2, NR1I3 | GPR84 193/4885HTR2A 241/4885TDO2 809/4885 |
| US-20210214362-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GPR84 3671/4885HTR2A 4579/4885TDO2 4294/4885 |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | GPR84 3671/4885HTR2A 4579/4885TDO2 4294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.